Nexvet Biopharma plc Company Profile (NASDAQ:NVET)

About Nexvet Biopharma plc (NASDAQ:NVET)

Nexvet Biopharma plc logoNexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company's platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal's immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company's advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NVET
  • CUSIP: N/A
  • Web: www.nexvet.com/
Average Prices:
  • 52 Week Range: $2.75 - $6.72
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.11
  • P/E Growth: 0.00
Profitability:
  • Return on Equity: -102.72%
  • Return on Assets: -89.82%
Debt:
  • Current Ratio: 5.34%
  • Quick Ratio: 5.34%
Misc:
  • Beta: 0.63
 

Frequently Asked Questions for Nexvet Biopharma plc (NASDAQ:NVET)

What is Nexvet Biopharma plc's stock symbol?

Nexvet Biopharma plc trades on the NASDAQ under the ticker symbol "NVET."

How were Nexvet Biopharma plc's earnings last quarter?

Nexvet Biopharma plc (NASDAQ:NVET) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. View Nexvet Biopharma plc's Earnings History.

Where is Nexvet Biopharma plc's stock going? Where will Nexvet Biopharma plc's stock price be in 2017?

1 brokers have issued 12 month price targets for Nexvet Biopharma plc's stock. Their forecasts range from $6.72 to $6.72. On average, they expect Nexvet Biopharma plc's share price to reach $6.72 in the next twelve months. View Analyst Ratings for Nexvet Biopharma plc.

Who are some of Nexvet Biopharma plc's key competitors?

When did Nexvet Biopharma plc IPO?

(NVET) raised $58 million in an IPO on Thursday, February 5th 2015. The company issued 4,000,000 shares at $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers.

Who owns Nexvet Biopharma plc stock?

Nexvet Biopharma plc's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (0.00%), Broadfin Capital LLC (0.00%), Kassirer Asset Management Corp (1.01%), GABELLI & Co INVESTMENT ADVISERS INC. (0.60%), GLG Partners LP (0.00%) and S. Muoio & CO. LLC (0.48%). Company insiders that own Nexvet Biopharma plc stock include Ashraf Hanna, Cormac G Kilty, David Gearing and Farallon Capital Management Ll. View Institutional Ownership Trends for Nexvet Biopharma plc.

Who bought Nexvet Biopharma plc stock? Who is buying Nexvet Biopharma plc stock?

Nexvet Biopharma plc's stock was bought by a variety of institutional investors in the last quarter, including Kassirer Asset Management Corp, GABELLI & Co INVESTMENT ADVISERS INC., GLG Partners LP, S. Muoio & CO. LLC, Harvest Management LLC and Glazer Capital LLC. Company insiders that have bought Nexvet Biopharma plc stock in the last two years include Ashraf Hanna, Cormac G Kilty, David Gearing and Farallon Capital Management Ll. View Insider Buying and Selling for Nexvet Biopharma plc.

How do I buy Nexvet Biopharma plc stock?

Shares of Nexvet Biopharma plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nexvet Biopharma plc's stock price today?

One share of Nexvet Biopharma plc stock can currently be purchased for approximately $6.72.


MarketBeat Community Rating for Nexvet Biopharma plc (NASDAQ NVET)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  140
MarketBeat's community ratings are surveys of what our community members think about Nexvet Biopharma plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Nexvet Biopharma plc (NASDAQ:NVET) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $6.72 (0.00% downside)

Analysts' Ratings History for Nexvet Biopharma plc (NASDAQ:NVET)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/24/2017Credit Suisse GroupDowngradeOutperform -> Neutral$8.00 -> $6.72LowView Rating Details
11/24/2015Cowen and CompanyReiterated RatingBuy$13.00N/AView Rating Details
11/24/2015Piper Jaffray CompaniesReiterated RatingOverweight$17.00 -> $13.00N/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Nexvet Biopharma plc (NASDAQ:NVET)
Earnings by Quarter for Nexvet Biopharma plc (NASDAQ:NVET)
Earnings History by Quarter for Nexvet Biopharma plc (NASDAQ NVET)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/20173/31/2017($0.49)($0.51)ViewN/AView Earnings Details
2/10/201712/31/2016($0.37)($0.46)ViewN/AView Earnings Details
11/4/2016Q1($0.41)($0.44)ViewN/AView Earnings Details
9/2/2016Q4 2016($0.48)($0.34)ViewN/AView Earnings Details
5/12/2016Q3($0.44)($0.50)ViewN/AView Earnings Details
11/5/2015Q1 2016($0.51)($0.35)ViewN/AView Earnings Details
5/8/2015Q115($0.20)($0.36)ViewN/AView Earnings Details
3/13/2015Q2 2015($0.55)($2.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nexvet Biopharma plc (NASDAQ:NVET)
Current Year EPS Consensus Estimate: $-1.75 EPS
Next Year EPS Consensus Estimate: $-1.10 EPS

Dividends

Dividend History for Nexvet Biopharma plc (NASDAQ:NVET)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nexvet Biopharma plc (NASDAQ:NVET)
Insider Ownership Percentage: 37.00%
Institutional Ownership Percentage: 48.38%
Insider Trades by Quarter for Nexvet Biopharma plc (NASDAQ:NVET)
Institutional Ownership by Quarter for Nexvet Biopharma plc (NASDAQ:NVET)
Insider Trades by Quarter for Nexvet Biopharma plc (NASDAQ:NVET)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/4/2016David GearingInsiderBuy11,113$3.33$37,006.29View SEC Filing  
3/2/2016Ashraf HannaDirectorBuy1,500$3.20$4,800.00View SEC Filing  
2/26/2016Farallon Capital Management LlInsiderBuy435,000$3.19$1,387,650.00View SEC Filing  
2/24/2016Cormac G KiltyDirectorBuy3,000$3.17$9,510.00View SEC Filing  
9/10/2015Farallon Capital Management LlInsiderBuy11,100$6.46$71,706.00View SEC Filing  
9/9/2015Cormac G KiltyDirectorBuy10,000$4.79$47,900.00View SEC Filing  
2/10/2015One Funds Management Ltd Atf AMajor ShareholderBuy100,000$10.00$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Nexvet Biopharma plc (NASDAQ:NVET)
Latest Headlines for Nexvet Biopharma plc (NASDAQ:NVET)
Source:
DateHeadline
americanbankingnews.com logoNexvet Biopharma plc (NVET) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - August 24 at 1:15 AM
finance.yahoo.com logoNexvet Biopharma plc ("Nexvet") Rule 17(d) Announcement
finance.yahoo.com - July 29 at 5:43 AM
finance.yahoo.com logoNexvet Biopharma plc ("Nexvet") Rule 17(c) Announcement
finance.yahoo.com - July 11 at 6:05 AM
finance.yahoo.com logoNexvet Biopharma plc ("Nexvet") Supplement Announcement
finance.yahoo.com - July 4 at 2:25 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Nexvet Biopharma plc and Encourages Investors to Contact the Firm for Additional Information
finance.yahoo.com - June 22 at 8:05 AM
finance.yahoo.com logoWeissLaw LLP Files Class Action Lawsuit Against Nexvet Biopharma PLC
finance.yahoo.com - June 19 at 6:01 PM
finance.yahoo.com logoNexvet Biopharma plc ("Nexvet") Rule 15 Announcement
finance.yahoo.com - June 16 at 8:21 AM
finance.yahoo.com logoNexvet Biopharma plc ("Nexvet") Rule 17(b) Announcement
finance.yahoo.com - June 7 at 12:42 AM
finance.yahoo.com logoNexvet Biopharma plc ("Nexvet") Rule 17 Announcement
finance.yahoo.com - June 2 at 8:51 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Filing of a Complaint Concerning Whether the Sale of Nexvet Biopharma Public Limited Company to Zoetis Inc. for $6.72 Per Share is Fair to Shareholders
finance.yahoo.com - June 2 at 8:51 PM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 18 at 9:02 PM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - May 12 at 2:02 PM
finance.yahoo.com logoNexvet Biopharma plc ("Nexvet") Rule 2.10 Announcement
finance.yahoo.com - May 12 at 12:26 AM
finance.yahoo.com logoNexvet Reports Financial Results for Third Quarter of Fiscal Year 2017
finance.yahoo.com - May 11 at 9:17 AM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Earns Coverage Optimism Score of -0.12
www.americanbankingnews.com - May 4 at 12:08 PM
americanbankingnews.com logo Brokerages Expect Nexvet Biopharma plc (NVET) Will Post Earnings of -$0.47 Per Share
www.americanbankingnews.com - May 3 at 12:04 AM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Getting Somewhat Negative Media Coverage, Study Finds
www.americanbankingnews.com - May 1 at 4:42 PM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Earns Daily Media Sentiment Rating of 0.09
www.americanbankingnews.com - April 28 at 8:22 PM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Receives Daily Media Sentiment Rating of 0.40
www.americanbankingnews.com - April 25 at 11:48 AM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Stock Rating Lowered by Credit Suisse Group AG
www.americanbankingnews.com - April 24 at 9:10 PM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Given Media Impact Rating of -0.08
www.americanbankingnews.com - April 19 at 12:11 PM
seekingalpha.com logoZoetis To Acquire Nexvet Biopharma For Animal Pain Management
seekingalpha.com - April 17 at 6:08 PM
finance.yahoo.com logoZoetis (ZTS) Inks Agreement to Acquire Nexvet Biopharma
finance.yahoo.com - April 17 at 6:08 PM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Earns Daily Media Impact Score of 0.28
www.americanbankingnews.com - April 15 at 2:55 PM
businesswire.com logoZoetis to Acquire Nexvet for US$6.72 in Cash Per Share
www.businesswire.com - April 13 at 6:41 PM
americanbankingnews.com logo Analysts Anticipate Nexvet Biopharma plc (NVET) Will Announce Earnings of -$0.47 Per Share
www.americanbankingnews.com - April 11 at 6:06 PM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 11 at 9:55 AM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 11 at 9:28 AM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 5 at 1:46 PM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 7:05 AM
americanbankingnews.com logoNexvet Biopharma plc (NVET) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 23 at 11:58 PM
biz.yahoo.com logoNEXVET BIOPHARMA PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - March 13 at 10:00 AM
finance.yahoo.com logoNexvet to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - March 2 at 8:58 AM
us.rd.yahoo.com logoNexvet Reports Financial Results for Second Quarter of Fiscal Year 2017
us.rd.yahoo.com - February 10 at 7:54 PM
biz.yahoo.com logoQ2 2017 Nexvet Biopharma plc Earnings Release - Time Not Supplied
biz.yahoo.com - February 10 at 7:54 PM
finance.yahoo.com logoNexvet Announces Initiation of Pivotal Efficacy Study of Frunevetmab in Cats
finance.yahoo.com - December 12 at 10:00 AM
biz.yahoo.com logoNEXVET BIOPHARMA PLC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission
biz.yahoo.com - November 18 at 9:45 AM
finance.yahoo.com logoNexvet to Present at the 25th Annual Credit Suisse Healthcare Conference
finance.yahoo.com - October 19 at 11:35 AM
finance.yahoo.com logoNEXVET BIOPHARMA PLC Financials
finance.yahoo.com - September 7 at 6:39 PM
biz.yahoo.com logoNEXVET BIOPHARMA PLC Files SEC form 10-K, Annual Report
biz.yahoo.com - September 2 at 11:21 AM
biz.yahoo.com logoQ4 2016 Nexvet Biopharma plc Earnings Release - Time Not Supplied
biz.yahoo.com - September 2 at 11:21 AM
biz.yahoo.com logoNEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
biz.yahoo.com - September 2 at 11:21 AM
finance.yahoo.com logoNexvet Announces Publication of Two Peer-Reviewed Journal Articles Profiling Frunevetmab (NV-02) and Presentation at the Veterinary Pain Short Course Conference
finance.yahoo.com - July 20 at 5:30 AM

Social

Chart

Nexvet Biopharma plc (NVET) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff